NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
72189-0589-30 | 72189-0589 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 15, 2024 | In Use | |
68382-0916-34 | 68382-0916 | methylprednisolone | methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
16590-0326-15 | 16590-0326 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 26, 1974 | In Use | |
33261-0417-06 | 33261-0417 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
45963-0607-56 | 45963-0607 | Vinorelbine | Vinorelbine | 10.0 mg/mL, 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Mar 1, 2015 | In Use | |
62135-0490-30 | 62135-0490 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 17, 2022 | In Use | ||
33261-0417-30 | 33261-0417 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
67296-0600-02 | 67296-0600 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 12, 2003 | In Use | |
80978-0641-01 | 80978-0641 | Melphalan | IVRA | 90.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 19, 2025 | In Use | |
68001-0468-36 | 68001-0468 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Dec 9, 2020 | In Use | |
70518-3922-00 | 70518-3922 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov 22, 2023 | In Use | ||
00069-0324-01 | 00069-0324 | Pegfilgrastim-apgf | NYVEPRIA | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Dec 15, 2020 | In Use | |
50090-1704-02 | 50090-1704 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb 18, 2015 | In Use | ||
00955-1746-01 | 00955-1746 | Clofarabine | Clofarabine | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | May 11, 2017 | In Use | |
64380-0128-02 | 64380-0128 | Cyclosporine | Cyclosporine | 50.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Aug 16, 2022 | In Use | |
00054-9817-29 | 00054-9817 | PredniSONE | PredniSONE | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 23, 2020 | In Use | |
70377-0013-22 | 70377-0013 | Everolimus | EVEROLIMUS | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2021 | In Use | |
16714-0727-01 | 16714-0727 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jun 15, 2017 | In Use | |
25021-0242-02 | 25021-0242 | Fludarabine phosphate | Fludarabine phosphate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Oct 15, 2016 | In Use | |
61919-0545-30 | 61919-0545 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 1, 2015 | In Use | |
55513-0141-01 | 55513-0141 | trastuzumab-anns | Kanjinti | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 28, 2019 | In Use | |
57277-0105-05 | 57277-0105 | carboplatin Injection | Carboplatin | 50.0 mg/5mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 29, 2016 | In Use | |
68083-0259-01 | 68083-0259 | Melphalan hydrochloride | Melphalan hydrochloride | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jun 10, 2019 | In Use | ||
81864-0101-30 | 81864-0101 | Momelotinib | Ojjaara | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Sep 15, 2023 | In Use | |
82249-0011-12 | 82249-0011 | Abiraterone acetate | ABIRTEGA | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral, Oral | Jan 17, 2025 | In Use |
Found 11564 results — Export these results